计量低温喷雾治疗慢性支气管炎:前瞻性假对照SPRAY-CB试验结果
SPRAY-CB是一项前瞻性假对照试验,评估计量低温喷雾(MCS)治疗COPD伴慢性支气管炎的安全性与有效性。203例患者按2:1随机接受两次支气管镜治疗(间隔30-60天),MCS组136例、假对照组67例,随访12个月。MCS组SGRQ总分改善显著优于对照组(差值-5.9,95%CI -11.6至-0.2,p=0.0422),CAT总分亦显著改善(差值-3.4,95%CI -5.8至-1.0,p=0.005)。
要点
- MCS组SGRQ总分较对照组显著改善,差值-5.9(95%CI -11.6至-0.2,p=0.0422)。
- MCS组CAT总分较对照组显著改善,差值-3.4(95%CI -5.8至-1.0,p=0.005)。
- MCS组与对照组AECOPD发生率分别为70.6%与67.2%,严重AECOPD分别为21.3%与26.9%。
核心结论
- MCS治疗使COPD伴慢性支气管炎患者SGRQ总分和CAT总分显著改善。
- MCS组严重AECOPD发生率较假对照组更低,风险-获益安全性可接受。
研究设计与样本
- 前瞻性假对照试验, eligible患者按2:1随机接受两次支气管镜治疗(间隔30-60天),伴或不伴MCS。
- 共203例患者纳入评估,MCS组136例,假对照组67例,安全性及临床有效性随访至MCS治疗后12个月。
主要发现
- MCS组SGRQ总分改善显著优于对照组,治疗差值-5.9(95%CI -11.6至-0.2,p=0.0422)。
- MCS组CAT总分改善显著优于对照组,治疗差值-3.4(95%CI -5.8至-1.0,p=0.005)。
- AECOPD(所有严重程度)发生率MCS组70.6%、对照组67.2%;严重AECOPD发生率MCS组21.3%、对照组26.9%。
- 每次MCS治疗的围手术期气胸发生率为3.6%(n/N=10/276)。
- 研究期间共8例死亡,MCS组6例(4.3%)、对照组2例(2.9%),均与器械或操作无关;未发生非预期器械不良效应。
临床怎么用
- 对于COPD伴慢性支气管炎患者,MCS可作为改善健康相关生活质量(SGRQ、CAT)的干预选择。
- MCS围手术期气胸发生率为3.6%,需关注操作相关风险,但严重AECOPD发生率在MCS组更低。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE: COPD with chronic bronchitis is characterized by productive cough with sputum and mucociliary dysfunction, contributing to morbidity and impaired quality of life. The RejuvenAir® System, a cryosurgical device delivering metered doses of medical-grade liquid nitrogen (i.e., Metered Cryospray [MCS]) to bronchial airways, may stimulate healthy epithelial cell regeneration. OBJECTIVES: To assess the safety and effectiveness of MCS treatment in patients with COPD and CB. METHODS: Eligible patients were randomized 2:1 to receive two bronchoscopies with therapeutic mucus clearance, with or without MCS treatment (i.e., MCS or control group, respectively), 30-60 days apart. Safety and clinical effectiveness outcomes were assessed 12 months post-MCS treatment. MEASUREMENTS AND MAIN RESULTS: Overall, 203 patients (MCS: N = 136; sham: N = 67) were evaluated. MCS-treated patients had significantly greater improvement in Total St. George's Respiratory Questionnaire (SGRQ) scores versus controls (treatment difference [95% confidence interval; CI]: -5.9 [-11.6, -0.2]; p = 0.0422), and Total COPD Assessment Test (CAT) scores (treatment difference [95% CI]: -3.4 [-5.8, -1.0]; p = 0.005). Acute exacerbation of COPD (AECOPD; all severities) rates were 70.6% (MCS group) versus 67.2% (control group). Severe AECOPD rates were 21.3% (MCS group) versus 26.9% (control group). Periprocedural pneumothoraces rate per number of MCS treatments delivered was 3.6% (n/N=10/276). Eight deaths, 6 (4.3%; MCS) and 2 (2.9%; control), occurred during the study, none were device- or procedure-related. No unanticipated adverse device effects occurred. CONCLUSIONS: MCS treatment demonstrated significant improvement in Total SGRQ and CAT scores, greater reductions in severe AECOPD rates compared to sham, and an acceptable risk-benefit safety profile in patients with COPD and CB.
引用
- Criner GJ, Browning RF, Abu-Hijleh M, et al. Metered-Dose Liquid Nitrogen Cryospray for Chronic Bronchitis: Results From the Prospective, Sham-Controlled Trial (SPRAY-CB). Am J Respir Crit Care Med. 2026. PMID: 42768446. doi:10.1093/ajrccm/aamag502
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。